Background: The significance of silent ischemia after acute myocardial infarction (MI) has been questioned. Objective: The aim of this study was to assess the risk for cardiac events in patients with silent ischemia after thrombolytic-treated first acute MI. Methods and Results: The Danish Trial in Acute Myocardial Infarction randomized 505 patients to conservative treatment after thrombolytic-treated first acute MI. For this analysis, patients were included if they demonstrated silent ischemia, i.e. ST deviations during exercise but without angina, during a symptom-limited bicycle exercise test. A total of 287 patients had silent postinfarct inducible ischemia. The 1-year incidence rate of combined cardiac endpoints, defined as death, reinfarction, need for revascularization or admission with unstable angina, was 22%. The level of maximum ST change during a stress test was used to categorize patients into three groups: group A: ST elevation (n = 54, 1-year event rate 15%); group B: >1 to <2 mm of ST depression (n = 86, 1-year event rate 22%); group C: >2 mm of ST depression during a stress test (n = 147, 1-year event rate 29%). Using a Cox proportional hazards model, the predictor of cardiovascular endpoints was the level of ST depression during a stress test (relative risk 2.4, 95% confidence limits 1.1–5.0, group C versus group A). Conclusion: This study identifies ST depression of more than 2 mm during a stress test as a significant risk factor for cardiac morbidity.

Keywords:
Silent ischemia, Exercise test, Myocardial infarction, Prognosis
This content is only available via PDF.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.